Treatment Options for Inoperable and Metastatic Malignant Melanoma:@0.248549:0.035749:0.914584:0.035749:0.914584:0.019993:0.248549:0.019993:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.016722:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006042:0.012604:0.005792:0.005330:0.004349:0.011738:0.012604:0.013123:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330:0.013143:0.011738:0.013181:0.005330:0.017684:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.017684:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.005330:0.017684:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
75:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
nivolumab may provide long-term survival :@0.084848:0.096166:0.481096:0.096166:0.481096:0.080410:0.084848:0.080410:0.011738:0.003848:0.010660:0.012604:0.003848:0.011699:0.018049:0.013143:0.013123:0.005253:0.018049:0.013143:0.010314:0.005253:0.013123:0.005715:0.012604:0.010660:0.003848:0.013181:0.012508:0.005253:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006319:0.018049:0.005253:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
in up to 50% of patients.:@0.084848:0.112609:0.306117:0.112609:0.306117:0.096854:0.084848:0.096854:0.003848:0.011738:0.005330:0.011699:0.013123:0.005330:0.006523:0.012604:0.005330:0.010660:0.010660:0.014913:0.005330:0.012604:0.006042:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
Despite these important clinical  ben-:@0.103032:0.129053:0.475769:0.129053:0.475769:0.113297:0.103032:0.113297:0.014316:0.012508:0.007466:0.013123:0.003848:0.006523:0.012508:0.012854:0.006523:0.011738:0.012508:0.007466:0.012508:0.012854:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.012854:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330:0.007535:0.013123:0.012508:0.011738:0.006388
efits,  immune-checkpoint  inhibitors  are :@0.084848:0.145497:0.481094:0.145497:0.481094:0.129741:0.084848:0.129741:0.012508:0.004686:0.004686:0.006523:0.007466:0.005330:0.005330:0.010968:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006388:0.012450:0.011738:0.012508:0.012450:0.009660:0.013123:0.012604:0.003848:0.011738:0.006523:0.005330:0.010966:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330:0.010976:0.013143:0.005715:0.012508:0.005330
associated with a unique spectrum  of :@0.084848:0.161941:0.481096:0.161941:0.481096:0.146185:0.084848:0.146185:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.013297:0.015990:0.003848:0.006523:0.011738:0.013297:0.013143:0.013297:0.011699:0.011738:0.003848:0.013123:0.011699:0.012508:0.013297:0.007466:0.013123:0.012508:0.012450:0.006523:0.005792:0.011699:0.018049:0.005330:0.007955:0.012604:0.006042:0.005330
side effects termed immune-related ad-:@0.084848:0.178385:0.475744:0.178385:0.475744:0.162629:0.084848:0.162629:0.007466:0.003848:0.013181:0.012508:0.009698:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.009698:0.006523:0.012508:0.006323:0.018049:0.012508:0.013181:0.009698:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006388:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.009698:0.013143:0.013181:0.006388
verse events (irAEs). These may occur  at :@0.084848:0.194829:0.481078:0.194829:0.481078:0.179073:0.084848:0.179073:0.010660:0.012508:0.005792:0.007466:0.012508:0.008467:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.008467:0.007100:0.003848:0.005792:0.014239:0.010314:0.007466:0.007100:0.005330:0.008467:0.008197:0.011738:0.012508:0.007466:0.012508:0.008467:0.018049:0.013143:0.010314:0.008467:0.012604:0.012450:0.012450:0.011699:0.005792:0.005330:0.003127:0.013143:0.006523:0.005330
any time during the course  of treatment :@0.084848:0.211273:0.481111:0.211273:0.481111:0.195517:0.084848:0.195517:0.013143:0.011738:0.010314:0.008409:0.006523:0.003848:0.018049:0.012508:0.008409:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.008409:0.006523:0.011738:0.012508:0.008409:0.012450:0.012604:0.011699:0.005792:0.007466:0.012508:0.005330:0.003069:0.012604:0.006042:0.008409:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
and may involve any organ system. The :@0.084848:0.227716:0.481061:0.227716:0.481061:0.211960:0.084848:0.211960:0.013143:0.011738:0.013181:0.008986:0.018049:0.013143:0.010314:0.008986:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.008986:0.013143:0.011738:0.010314:0.008986:0.012604:0.005804:0.012950:0.013143:0.011738:0.008986:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.005330:0.008986:0.008197:0.011738:0.012508:0.005330
most  commonly occurring  irAEs  include :@0.084848:0.244160:0.481088:0.244160:0.481088:0.228404:0.084848:0.228404:0.018049:0.012604:0.007466:0.006523:0.005330:0.006261:0.012450:0.012604:0.018049:0.018049:0.012604:0.011726:0.003848:0.010314:0.011603:0.012604:0.012450:0.012450:0.011699:0.005792:0.005792:0.003848:0.011738:0.012950:0.005330:0.006248:0.003848:0.005792:0.014239:0.010314:0.007466:0.005330:0.006263:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330
dermatitis, enterocolitis, thyroid dysfunc-:@0.084848:0.260604:0.475777:0.260604:0.475777:0.244848:0.084848:0.244848:0.013181:0.012508:0.006323:0.018049:0.013143:0.006523:0.003848:0.006523:0.003848:0.007466:0.005330:0.011161:0.012508:0.011738:0.006523:0.012508:0.005709:0.012604:0.012450:0.012604:0.003848:0.003848:0.006523:0.003848:0.007466:0.005330:0.011161:0.006523:0.011738:0.010314:0.005709:0.012604:0.003848:0.013181:0.011161:0.013181:0.010314:0.007466:0.006042:0.011699:0.011738:0.012450:0.006388
tion and fatigue. These may also include :@0.084848:0.277048:0.481088:0.277048:0.481088:0.261292:0.084848:0.261292:0.006523:0.003848:0.012604:0.011738:0.007639:0.013143:0.011738:0.013181:0.007639:0.006042:0.013143:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330:0.007639:0.008197:0.011738:0.012508:0.007466:0.012508:0.007639:0.018049:0.013143:0.010314:0.007639:0.013143:0.003848:0.007466:0.012604:0.007639:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330
pneumonitis, hypophysitis and associated :@0.084848:0.293492:0.481084:0.293492:0.481084:0.277736:0.084848:0.277736:0.013123:0.011738:0.012508:0.011699:0.018049:0.012604:0.011738:0.003848:0.006523:0.003848:0.007466:0.005330:0.006639:0.011738:0.010314:0.013123:0.012604:0.013123:0.011738:0.010314:0.007466:0.003848:0.006523:0.003848:0.007466:0.006654:0.013143:0.011738:0.013181:0.006639:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
endocrinopathies,  uveitis, hepatitis,  neu-:@0.084848:0.309936:0.475760:0.309936:0.475760:0.294180:0.084848:0.294180:0.012508:0.011738:0.013181:0.012604:0.012450:0.005792:0.003848:0.011738:0.012604:0.013123:0.013143:0.006523:0.011738:0.003848:0.012508:0.007466:0.005330:0.005330:0.005494:0.011699:0.010660:0.012508:0.003848:0.006523:0.003848:0.007466:0.005330:0.010833:0.011738:0.012508:0.013123:0.013143:0.006523:0.003848:0.006523:0.003848:0.007466:0.005330:0.005330:0.005515:0.011738:0.012508:0.011699:0.006388
rological, cardiac, rheumatological  and :@0.084848:0.326380:0.481078:0.326380:0.481078:0.310624:0.084848:0.310624:0.005713:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330:0.010660:0.012450:0.013143:0.005677:0.013181:0.003848:0.013143:0.012450:0.005330:0.010660:0.006342:0.011738:0.012508:0.011699:0.018049:0.013143:0.006523:0.012592:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330:0.005342:0.013143:0.011738:0.013181:0.005330
renal toxicities. In certain cases, these re-:@0.084848:0.342823:0.475773:0.342823:0.475773:0.327067:0.084848:0.327067:0.005713:0.012508:0.011738:0.013143:0.003848:0.007331:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.007331:0.004349:0.011738:0.007331:0.012450:0.012508:0.005792:0.006523:0.013143:0.003848:0.011738:0.007331:0.012450:0.013143:0.007466:0.012508:0.007466:0.005330:0.007331:0.006523:0.011738:0.012508:0.007466:0.012508:0.007331:0.005713:0.012508:0.006388
actions have been fatal. Experience with :@0.084848:0.359267:0.481103:0.359267:0.481103:0.343511:0.084848:0.343511:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.007012:0.011738:0.013143:0.010660:0.012508:0.007023:0.013123:0.012508:0.012508:0.011738:0.007008:0.006042:0.013143:0.006523:0.013143:0.003848:0.005330:0.007023:0.010314:0.009236:0.013123:0.012508:0.005792:0.003848:0.012508:0.011738:0.012450:0.012508:0.007008:0.015990:0.003848:0.006523:0.011738:0.005330
these agents has allowed for  effective :@0.084848:0.375711:0.481094:0.375711:0.481094:0.359955:0.084848:0.359955:0.006523:0.011738:0.012508:0.007466:0.012508:0.012161:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.012161:0.011738:0.013143:0.007466:0.012161:0.013143:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.012161:0.006042:0.012604:0.005792:0.005330:0.006821:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330
management of irAEs, with improved pa-:@0.084848:0.392155:0.475750:0.392155:0.475750:0.376399:0.084848:0.376399:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.006887:0.012604:0.006042:0.006895:0.003848:0.005792:0.014239:0.010314:0.007466:0.005330:0.006896:0.015990:0.003848:0.006523:0.011738:0.006898:0.003848:0.018049:0.013123:0.005715:0.012604:0.010660:0.012508:0.013181:0.006898:0.013123:0.013143:0.006388
tient education, clinical monitoring, early :@0.084848:0.408599:0.481105:0.408599:0.481105:0.392843:0.084848:0.392843:0.006523:0.003848:0.012508:0.011738:0.006523:0.007735:0.012508:0.013181:0.011699:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.007735:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.007753:0.018049:0.012604:0.011738:0.003848:0.006523:0.012604:0.005792:0.003848:0.011738:0.012950:0.005330:0.007735:0.012508:0.013143:0.005792:0.003848:0.010314:0.005330
recognition and prompt, algorithm-based :@0.084848:0.425043:0.481086:0.425043:0.481086:0.409287:0.084848:0.409287:0.005713:0.012508:0.012450:0.012604:0.012950:0.011738:0.003848:0.006523:0.003848:0.012604:0.011738:0.005842:0.013143:0.011738:0.013181:0.005857:0.013123:0.005715:0.012604:0.018049:0.013123:0.006523:0.005330:0.005850:0.013143:0.003848:0.012950:0.012604:0.005792:0.003848:0.006523:0.011738:0.018049:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330
initiation of appropriate treatment.:@0.084848:0.441487:0.408336:0.441487:0.408336:0.425731:0.084848:0.425731:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.012604:0.006042:0.005330:0.013143:0.013123:0.013123:0.005711:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330:0.006523:0.005703:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
TARGETED THERAPY:@0.084848:0.474685:0.280266:0.474685:0.280266:0.456870:0.084848:0.456870:0.008980:0.015822:0.012401:0.017960:0.011118:0.008980:0.011118:0.014966:0.005987:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
Approximately half of patients with meta-:@0.084848:0.492275:0.475765:0.492275:0.475765:0.476519:0.084848:0.476519:0.014239:0.013123:0.013123:0.005713:0.012604:0.009236:0.003848:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.006331:0.011738:0.013143:0.003848:0.006042:0.006331:0.012604:0.006042:0.006321:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006331:0.015990:0.003848:0.006523:0.011738:0.006331:0.018049:0.012508:0.006523:0.013143:0.006388
static melanoma will show BRAF mutations. :@0.084848:0.508718:0.481107:0.508718:0.481107:0.492963:0.084848:0.492963:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.003868:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.003868:0.015990:0.003848:0.003848:0.003848:0.003868:0.007466:0.011738:0.012604:0.015990:0.003868:0.011045:0.011680:0.014239:0.009333:0.003868:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330
BRAF  inhibitors  vemurafenib  and  dab-:@0.084848:0.525162:0.475748:0.525162:0.475748:0.509406:0.084848:0.509406:0.011045:0.011680:0.014239:0.009333:0.005330:0.009933:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330:0.009937:0.010660:0.012508:0.018049:0.011699:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005330:0.009939:0.013143:0.011738:0.013181:0.005330:0.009937:0.013181:0.013143:0.013123:0.006388
rafenib have shown  improved response :@0.084848:0.541606:0.481096:0.541606:0.481096:0.525850:0.084848:0.525850:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.011084:0.011738:0.013143:0.010660:0.012508:0.011084:0.007466:0.011738:0.012604:0.015990:0.011738:0.005330:0.005742:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.011084:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330
rates, progression-free survival and overall :@0.084848:0.558050:0.481078:0.558050:0.481078:0.542294:0.084848:0.542294:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.005911:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005705:0.012508:0.012508:0.005913:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013154:0.003848:0.005927:0.013143:0.011738:0.013181:0.005917:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005330
survival  when compared with standard :@0.084848:0.574494:0.481086:0.574494:0.481086:0.558738:0.084848:0.558738:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.006906:0.015990:0.011738:0.012508:0.011738:0.012219:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.012219:0.015990:0.003848:0.006523:0.011738:0.012219:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005678:0.013181:0.005330
chemotherapy. :@0.084848:0.590938:0.235997:0.590938:0.235997:0.575182:0.084848:0.575182:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
Patients treated with BRAF inhibitors show :@0.103032:0.607382:0.481088:0.607382:0.481088:0.591626:0.103032:0.591626:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.003352:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.003354:0.015990:0.003848:0.006523:0.011738:0.003356:0.011045:0.011680:0.014239:0.009333:0.003352:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.003352:0.007466:0.011738:0.012604:0.015990:0.005330
median response durations of around five :@0.084848:0.623825:0.481096:0.623825:0.481096:0.608069:0.084848:0.608069:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.006017:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.006015:0.013181:0.011699:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.006011:0.012604:0.006042:0.006015:0.013143:0.005715:0.012604:0.011699:0.011738:0.013181:0.006007:0.004686:0.004686:0.010660:0.012508:0.005330
to seven months.:@0.084848:0.640269:0.241564:0.640269:0.241564:0.624513:0.084848:0.624513:0.006523:0.012604:0.004637:0.007466:0.012508:0.010660:0.012508:0.011738:0.004637:0.018049:0.012604:0.011738:0.006523:0.011724:0.007466:0.005330
10,11:@0.241571:0.634645:0.269539:0.634645:0.269539:0.625460:0.241571:0.625460:0.006215:0.006215:0.003107:0.006215:0.006215
 Treatment is generally :@0.269546:0.640264:0.481089:0.640264:0.481089:0.624508:0.269546:0.624508:0.004637:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004637:0.003848:0.007466:0.004651:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.003848:0.010314:0.005330
well tolerated. :@0.084857:0.656708:0.223672:0.656708:0.223672:0.640952:0.084857:0.640952:0.015990:0.012508:0.003848:0.003848:0.005330:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.013181:0.005330:0.005330
The  most frequently occurring  toxicities :@0.103041:0.673152:0.481102:0.673152:0.481102:0.657396:0.103041:0.657396:0.008197:0.011738:0.012508:0.005330:0.003031:0.018049:0.012604:0.007466:0.006523:0.008370:0.006042:0.005711:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.008370:0.012604:0.012450:0.012450:0.011699:0.005792:0.005792:0.003848:0.011738:0.012950:0.005330:0.003021:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330
include arthralgia, fatigue and cutane-:@0.084857:0.689596:0.475776:0.689596:0.475776:0.673840:0.084857:0.673840:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.011796:0.013143:0.005792:0.006523:0.011738:0.005792:0.013133:0.003848:0.012950:0.003848:0.013143:0.005330:0.011796:0.006042:0.013143:0.006523:0.003848:0.012950:0.011699:0.012508:0.011796:0.013143:0.011738:0.013181:0.011796:0.012450:0.011699:0.006523:0.013143:0.011738:0.012508:0.006388
ous events (rash, photosensitivity and the :@0.084857:0.706040:0.481122:0.706040:0.481122:0.690284:0.084857:0.690284:0.012604:0.011699:0.007466:0.007408:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.007408:0.007100:0.005792:0.013143:0.007466:0.011738:0.005330:0.007395:0.013123:0.011738:0.012604:0.006523:0.012604:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.007408:0.013143:0.011738:0.013181:0.007408:0.006523:0.011738:0.012508:0.005330
development  of  squamous cell carcino-:@0.084857:0.722484:0.475778:0.722484:0.475778:0.706728:0.084857:0.706728:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.018049:0.012508:0.011738:0.006523:0.005330:0.004374:0.012604:0.006042:0.005330:0.004374:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.009717:0.012450:0.012508:0.003848:0.003848:0.009717:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.006388
mas). Small molecule inhibitors of MEK act :@0.084857:0.738927:0.481085:0.738927:0.481085:0.723171:0.084857:0.723171:0.018049:0.013143:0.007466:0.007100:0.005330:0.005534:0.009583:0.018049:0.013143:0.003848:0.003848:0.005538:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.012508:0.005523:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005523:0.012604:0.006042:0.005523:0.017684:0.010314:0.011372:0.005523:0.013143:0.012450:0.006523:0.005330
downstream of  BRAF  in the  MAP  kinase :@0.084857:0.755371:0.481102:0.755371:0.481102:0.739615:0.084857:0.739615:0.013181:0.012604:0.015990:0.011738:0.007466:0.006523:0.005709:0.012508:0.013143:0.018049:0.010179:0.012604:0.006042:0.005330:0.004839:0.011045:0.011680:0.014239:0.009333:0.005330:0.004839:0.003848:0.011738:0.010179:0.006523:0.011738:0.012508:0.005330:0.004836:0.017684:0.014239:0.011392:0.005330:0.004836:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.005330
pathway, and a combination  of  these :@0.084857:0.771815:0.481114:0.771815:0.481114:0.756059:0.084857:0.756059:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.005330:0.012277:0.013143:0.011738:0.013181:0.012277:0.013143:0.012277:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006935:0.012604:0.006042:0.005330:0.006937:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330
agents  with a BRAF  inhibitor has resulted :@0.084857:0.788259:0.481112:0.788259:0.481112:0.772503:0.084857:0.772503:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.003031:0.015990:0.003848:0.006523:0.011738:0.008370:0.013143:0.008370:0.011045:0.011680:0.014239:0.009333:0.005330:0.003029:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.008370:0.011738:0.013143:0.007466:0.008370:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.012508:0.013181:0.005330
in further improvement in progression-free :@0.084857:0.804703:0.481122:0.804703:0.481122:0.788947:0.084857:0.788947:0.003848:0.011738:0.006369:0.006042:0.011699:0.005792:0.006523:0.011738:0.012496:0.005792:0.006360:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.006358:0.003848:0.011738:0.006369:0.013123:0.005715:0.012604:0.012950:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005713:0.012508:0.012508:0.005330
and overall survival when compared with :@0.084857:0.821147:0.481101:0.821147:0.481101:0.805391:0.084857:0.805391:0.013143:0.011738:0.013181:0.006494:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.006504:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006504:0.015990:0.011738:0.012508:0.011738:0.006487:0.012450:0.012604:0.018049:0.013123:0.013143:0.005717:0.012508:0.013181:0.006494:0.015990:0.003848:0.006523:0.011738:0.005330
BRAF inhibition alone. Here, a median pro-:@0.084857:0.837591:0.475784:0.837591:0.475784:0.821835:0.084857:0.821835:0.011045:0.011680:0.014239:0.009333:0.004988:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.005003:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330:0.004986:0.013143:0.012508:0.005713:0.012508:0.005330:0.004988:0.013143:0.005003:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.004993:0.013123:0.005715:0.012604:0.006388
gression-free survival of between 11 to 14 :@0.084857:0.854034:0.481087:0.854034:0.481087:0.838278:0.084857:0.838278:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005715:0.012508:0.012508:0.006831:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006852:0.012604:0.006042:0.006831:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.006831:0.010660:0.010660:0.006845:0.006523:0.012604:0.006831:0.010660:0.010660:0.005330
months and a median overall survival ap-:@0.084857:0.870478:0.475767:0.870478:0.475767:0.854722:0.084857:0.854722:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.006146:0.013143:0.011738:0.013181:0.006158:0.013143:0.006158:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.006158:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.006158:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006169:0.013143:0.013123:0.006388
proaching two years has been achieved.  :@0.084857:0.886922:0.481087:0.886914:0.481087:0.871158:0.084857:0.871166:0.013123:0.005715:0.012604:0.013143:0.012450:0.011738:0.003848:0.011738:0.012950:0.003848:0.006523:0.015990:0.012604:0.003848:0.010314:0.012508:0.013143:0.005792:0.007466:0.003848:0.011738:0.013143:0.007466:0.003848:0.013123:0.012508:0.012508:0.011738:0.003848:0.013143:0.012450:0.011738:0.003848:0.012508:0.010660:0.012508:0.013181:0.005330:0.012421:-0.288351
12:@0.463323:0.881295:0.475753:0.881295:0.475753:0.872109:0.463323:0.872109:0.006215:0.006215
Importantly, the combined approach is :@0.084848:0.903358:0.481089:0.903358:0.481089:0.887602:0.084848:0.887602:0.004349:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330:0.011238:0.006523:0.011738:0.012508:0.011238:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.012508:0.013181:0.011238:0.013143:0.013123:0.013123:0.005717:0.012604:0.013143:0.012450:0.011738:0.011238:0.003848:0.007466:0.005330
well tolerated,  and  the  incidence  of  cu-:@0.084848:0.919802:0.475765:0.919802:0.475765:0.904046:0.084848:0.904046:0.015990:0.012508:0.003848:0.003848:0.008428:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.013181:0.005330:0.005330:0.003079:0.013143:0.011738:0.013181:0.005330:0.003085:0.006523:0.011738:0.012508:0.005330:0.003079:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.005330:0.003079:0.012604:0.006042:0.005330:0.003081:0.012450:0.011699:0.006388
taneous  squamous cell carcinoma was :@0.084848:0.936245:0.481078:0.936245:0.481078:0.920489:0.084848:0.920489:0.006523:0.013143:0.011738:0.012508:0.012604:0.011699:0.007466:0.005330:0.006571:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.011911:0.012450:0.012508:0.003848:0.003848:0.011911:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.011911:0.015990:0.013143:0.007466:0.005330
significantly decreased. Thus, for patients :@0.524248:0.096167:0.920491:0.096167:0.920491:0.080411:0.524248:0.080411:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.007993:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.005330:0.007989:0.008197:0.011738:0.011699:0.007466:0.005330:0.007988:0.006042:0.012604:0.005792:0.007980:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
who are candidates for targeted therapy, :@0.524248:0.112558:0.920493:0.112558:0.920493:0.096802:0.524248:0.096802:0.015990:0.011738:0.012604:0.005195:0.013143:0.005715:0.012508:0.005201:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.005201:0.006042:0.012604:0.005792:0.005194:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.012508:0.013181:0.005197:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
a combination of a BRAF and a MEK in-:@0.524248:0.128949:0.915119:0.128949:0.915119:0.113193:0.524248:0.113193:0.013143:0.008428:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.008428:0.012604:0.006042:0.008428:0.013143:0.008428:0.011045:0.011680:0.014239:0.009333:0.008428:0.013143:0.011738:0.013181:0.008428:0.013143:0.008428:0.017684:0.010314:0.011372:0.008428:0.003848:0.011738:0.006388
hibitor rather than a single agent is recom-:@0.524248:0.145340:0.915156:0.145340:0.915156:0.129584:0.524248:0.129584:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.004772:0.005792:0.013143:0.006523:0.011738:0.012508:0.005792:0.004772:0.006523:0.011738:0.013143:0.011738:0.004772:0.013143:0.004772:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.004772:0.013143:0.012950:0.012508:0.011738:0.006523:0.004772:0.003848:0.007466:0.004772:0.005713:0.012508:0.012450:0.012604:0.018049:0.006388
mended.:@0.524248:0.161731:0.610743:0.161731:0.610743:0.145975:0.524248:0.145975:0.018049:0.012508:0.011738:0.013181:0.012508:0.013181:0.005330
A  small proportion  of  acral and  mu-:@0.542432:0.178122:0.915165:0.178122:0.915165:0.162366:0.542432:0.162366:0.014239:0.005330:0.006873:0.007466:0.018049:0.013143:0.003848:0.003848:0.012219:0.013123:0.005715:0.012604:0.013123:0.012604:0.005792:0.006523:0.003848:0.012604:0.011738:0.005330:0.006862:0.012604:0.006042:0.005330:0.006873:0.013143:0.012450:0.005792:0.013143:0.003848:0.012219:0.013143:0.011738:0.013181:0.005330:0.006877:0.018049:0.011699:0.006388
cosal melanomas will harbour somatic :@0.524248:0.194513:0.920488:0.194513:0.920488:0.178757:0.524248:0.178757:0.012450:0.012604:0.007466:0.013143:0.003848:0.013835:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.007466:0.013835:0.015990:0.003848:0.003848:0.003848:0.013835:0.011738:0.013143:0.005792:0.013123:0.012604:0.011699:0.005792:0.013835:0.007466:0.012604:0.018049:0.013143:0.006523:0.003848:0.012450:0.005330
mutations or amplifications of KIT. Imatinib :@0.524248:0.210903:0.920478:0.210903:0.920478:0.195148:0.524248:0.195148:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.006119:0.012604:0.005792:0.006117:0.013143:0.018049:0.013123:0.003848:0.003848:0.004686:0.004686:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.006131:0.012604:0.006042:0.006119:0.011372:0.004349:0.006829:0.005330:0.006121:0.004349:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330
(small molecule inhibitor of KIT) has dem-:@0.524248:0.227294:0.915161:0.227294:0.915161:0.211538:0.524248:0.211538:0.007100:0.007466:0.018049:0.013143:0.003848:0.003848:0.007466:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.012508:0.007453:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007453:0.012604:0.006042:0.007451:0.011372:0.004349:0.008197:0.007100:0.007455:0.011738:0.013143:0.007466:0.007466:0.013181:0.012508:0.018049:0.006388
onstrated improved responses in patients :@0.524248:0.243685:0.920491:0.243685:0.920491:0.227929:0.524248:0.227929:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.007662:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.007678:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.007466:0.007678:0.003848:0.011738:0.007678:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with melanoma harbouring KIT mutations. :@0.524248:0.260076:0.920495:0.260076:0.920495:0.244320:0.524248:0.244320:0.015990:0.003848:0.006523:0.011738:0.006619:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.006619:0.011738:0.013143:0.005792:0.013123:0.012604:0.011699:0.005792:0.003848:0.011738:0.012950:0.006608:0.011372:0.004349:0.008197:0.006619:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330
However, these responses were of limited :@0.524248:0.276467:0.920478:0.276467:0.920478:0.260711:0.524248:0.260711:0.013143:0.012604:0.015990:0.012508:0.010660:0.012508:0.003768:0.005330:0.007177:0.006523:0.011738:0.012508:0.007466:0.012508:0.007177:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.007466:0.007177:0.015990:0.012508:0.005711:0.012508:0.007177:0.012604:0.006042:0.007177:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330
duration  and did not  translate  to  an  im-:@0.524248:0.292858:0.915163:0.292858:0.915163:0.277102:0.524248:0.277102:0.013181:0.011699:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.003273:0.013143:0.011738:0.013181:0.008621:0.013181:0.003848:0.013181:0.008621:0.011738:0.012604:0.006523:0.005330:0.003273:0.006523:0.005792:0.013143:0.011738:0.007466:0.003848:0.013143:0.006523:0.012508:0.005330:0.003279:0.006523:0.012604:0.005330:0.003275:0.013143:0.011738:0.005330:0.003281:0.003848:0.018049:0.006388
provement in survival.:@0.524248:0.309249:0.726370:0.309249:0.726370:0.293493:0.524248:0.293493:0.013123:0.005715:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330:0.003848:0.011738:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
CHEMOTHERAPY:@0.524242:0.342274:0.691865:0.342274:0.691865:0.324459:0.524242:0.324459:0.016677:0.014539:0.011118:0.019242:0.017960:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
At  present,  the  role  of  chemotherapy  is :@0.524242:0.359806:0.920479:0.359806:0.920479:0.344050:0.524242:0.344050:0.014239:0.006523:0.005330:0.004559:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.005330:0.005330:0.004557:0.006523:0.011738:0.012508:0.005330:0.004566:0.005713:0.012604:0.003848:0.012508:0.005330:0.004564:0.012604:0.006042:0.005330:0.004560:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004557:0.003848:0.007466:0.005330
limited to patients who have progressed :@0.524242:0.376197:0.920472:0.376197:0.920472:0.360441:0.524242:0.360441:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.008698:0.006523:0.012604:0.008698:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008698:0.015990:0.011738:0.012604:0.008698:0.011738:0.013143:0.010660:0.012508:0.008698:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330
on immunotherapy or where these treat-:@0.524242:0.392588:0.915149:0.392588:0.915149:0.376832:0.524242:0.376832:0.012604:0.011738:0.007812:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012496:0.005792:0.013143:0.013123:0.010314:0.007812:0.012604:0.005792:0.007812:0.015990:0.011738:0.012508:0.005709:0.012508:0.007812:0.006523:0.011738:0.012508:0.007466:0.012508:0.007812:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment  options  are  not  clinically  appropri-:@0.524242:0.408979:0.915151:0.408979:0.915151:0.393223:0.524242:0.393223:0.018049:0.012508:0.011738:0.006523:0.005330:0.003814:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.003818:0.013143:0.005715:0.012508:0.005330:0.003820:0.011738:0.012604:0.006523:0.005330:0.003812:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.003841:0.013143:0.013123:0.013123:0.005719:0.012604:0.013123:0.005792:0.003848:0.006388
ate, affordable or available. Chemother-:@0.524242:0.425370:0.915151:0.425370:0.915151:0.409614:0.524242:0.409614:0.013143:0.006523:0.012508:0.005330:0.007389:0.013143:0.006100:0.006042:0.012604:0.005671:0.013181:0.013143:0.013123:0.003848:0.012508:0.007389:0.012604:0.005792:0.007389:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330:0.007410:0.015644:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005777:0.006388
apy agents which have shown activity in :@0.524242:0.441761:0.920481:0.441761:0.920481:0.426005:0.524242:0.426005:0.013143:0.013123:0.010314:0.007293:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.007293:0.015990:0.011738:0.003848:0.012450:0.011738:0.007293:0.011738:0.013143:0.010660:0.012508:0.007293:0.007466:0.011738:0.012604:0.015990:0.011738:0.007293:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.007293:0.003848:0.011738:0.005330
melanoma  include dacarbazine,  temo-:@0.524242:0.458152:0.915151:0.458152:0.915151:0.442396:0.524242:0.442396:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.005330:0.006973:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.012315:0.013181:0.013143:0.012450:0.013143:0.005792:0.013123:0.013143:0.008178:0.003848:0.011738:0.012508:0.005330:0.005330:0.006968:0.006523:0.012508:0.018049:0.012594:0.006388
zolomide,  nitrosoureas  (carmustine  and :@0.524242:0.474543:0.920483:0.474543:0.920483:0.458787:0.524242:0.458787:0.008178:0.012604:0.003848:0.012604:0.018049:0.003848:0.013181:0.012508:0.005330:0.005330:0.008272:0.011738:0.003848:0.006523:0.005711:0.012604:0.007466:0.012604:0.011699:0.005711:0.012508:0.013143:0.007466:0.005330:0.008284:0.007100:0.012450:0.013143:0.006329:0.018049:0.011699:0.007466:0.006523:0.003848:0.011738:0.012508:0.005330:0.008278:0.013143:0.011738:0.013181:0.005330
lomustine),  platinum  compounds  (cispl-:@0.524242:0.490934:0.915151:0.490934:0.915151:0.475178:0.524242:0.475178:0.003848:0.012604:0.018049:0.011699:0.007466:0.006523:0.003848:0.011738:0.012508:0.007100:0.005330:0.005330:0.008357:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.005330:0.008357:0.012450:0.012604:0.018049:0.013123:0.012604:0.011699:0.011738:0.013181:0.007466:0.005330:0.008359:0.007100:0.012450:0.003848:0.007466:0.013123:0.003868:0.006388
atin and carboplatin) and albumin-bound :@0.524242:0.507325:0.920501:0.507325:0.920501:0.491569:0.524242:0.491569:0.013143:0.006523:0.003848:0.011738:0.004734:0.013143:0.011738:0.013181:0.004734:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.007100:0.004734:0.013143:0.011738:0.013181:0.004734:0.013143:0.003848:0.013123:0.011699:0.018049:0.003848:0.011738:0.006388:0.013123:0.012604:0.011699:0.011738:0.013181:0.005330
paclitaxel (nab-paclitaxel). These agents :@0.524242:0.523715:0.920481:0.523715:0.920481:0.507960:0.524242:0.507960:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.008967:0.007100:0.011738:0.013143:0.013123:0.006388:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.007100:0.005330:0.008967:0.008197:0.011738:0.012508:0.007466:0.012508:0.008967:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330
may be used as single agents, or as com-:@0.524242:0.540106:0.915182:0.540106:0.915182:0.524350:0.524242:0.524350:0.018049:0.013143:0.010314:0.005984:0.013123:0.012508:0.005975:0.011699:0.007466:0.012508:0.013181:0.005984:0.013143:0.007466:0.005984:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.005984:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.005967:0.012604:0.005792:0.005965:0.013143:0.007466:0.005984:0.012450:0.012604:0.018049:0.006388
bination regimens.:@0.524242:0.556497:0.696244:0.556497:0.696244:0.540741:0.524242:0.540741:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005709:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005330
CURRENT RECOMMENDATIONS:@0.524242:0.589852:0.866671:0.589852:0.866671:0.570255:0.524242:0.570255:0.018344:0.015052:0.013641:0.013641:0.012230:0.017404:0.009878:0.006585:0.013641:0.012230:0.018344:0.019756:0.021167:0.021167:0.012230:0.017404:0.016463:0.017404:0.009878:0.006585:0.019756:0.017404:0.012230
The mainstay of treatment for inoperable :@0.524242:0.608531:0.920493:0.608531:0.920493:0.592775:0.524242:0.592775:0.008197:0.011738:0.012508:0.007139:0.018049:0.013143:0.003848:0.011738:0.007466:0.006523:0.013143:0.010314:0.007154:0.012604:0.006042:0.007139:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007139:0.006042:0.012604:0.005792:0.007139:0.003848:0.011738:0.012604:0.013123:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330
or  metastatic melanoma  remains sys-:@0.524242:0.624922:0.915155:0.624922:0.915155:0.609166:0.524242:0.609166:0.012604:0.005792:0.005330:0.010949:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.016298:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.005330:0.010955:0.005713:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.016298:0.007466:0.010314:0.007466:0.006388
temic  therapy, with surgical metastatec-:@0.524242:0.641312:0.915176:0.641312:0.915176:0.625557:0.524242:0.625557:0.006523:0.012508:0.018049:0.003848:0.012450:0.005330:0.003300:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.008640:0.015990:0.003848:0.006523:0.011738:0.008640:0.007466:0.011699:0.005807:0.012950:0.003848:0.012450:0.013143:0.003848:0.008640:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.012508:0.012450:0.006388
tomy reserved for  a highly select group :@0.524242:0.657703:0.920481:0.657703:0.920481:0.641947:0.524242:0.641947:0.006523:0.012604:0.018049:0.010314:0.009948:0.005711:0.012508:0.007466:0.012508:0.005792:0.010660:0.012508:0.013181:0.009948:0.006042:0.012604:0.005792:0.005330:0.004609:0.013143:0.009948:0.011738:0.003848:0.012950:0.011738:0.003848:0.010314:0.009948:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.009948:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330
of patients. Primary systemic therapy ap-:@0.524242:0.674094:0.915155:0.674094:0.915155:0.658338:0.524242:0.658338:0.012604:0.006042:0.007859:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.007859:0.011392:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.007870:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.007870:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007859:0.013143:0.013123:0.006388
proaches include i) immunotherapy (anti-:@0.524242:0.690485:0.915161:0.690485:0.915161:0.674729:0.524242:0.674729:0.013123:0.005715:0.012604:0.013143:0.012450:0.011738:0.012508:0.007466:0.006023:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.006023:0.003848:0.007100:0.006023:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011728:0.012508:0.005792:0.013143:0.013123:0.010314:0.006023:0.007100:0.013143:0.011738:0.006523:0.003848:0.006388
PD-1 antibody alone or in combination :@0.524242:0.706876:0.920481:0.706876:0.920481:0.691120:0.524242:0.691120:0.011392:0.014316:0.006388:0.010660:0.011238:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.011238:0.013143:0.003848:0.012604:0.011738:0.012508:0.011238:0.012604:0.005792:0.011238:0.003848:0.011738:0.011238:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
with anti-CTLA-4) and ii) targeted therapy :@0.524242:0.723267:0.920476:0.723267:0.920476:0.707511:0.524242:0.707511:0.015990:0.003848:0.006523:0.011738:0.006177:0.013143:0.011738:0.006523:0.003848:0.006388:0.015644:0.008197:0.008890:0.014239:0.006379:0.010660:0.007100:0.006188:0.013143:0.011738:0.013181:0.006177:0.003848:0.003848:0.007100:0.006192:0.006523:0.013143:0.005807:0.012950:0.012508:0.006523:0.012508:0.013181:0.006177:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
(combination of a BRAF and a MEK inhibi-:@0.524242:0.739658:0.915151:0.739658:0.915151:0.723902:0.524242:0.723902:0.007100:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005850:0.012604:0.006042:0.005850:0.013143:0.005850:0.011045:0.011680:0.014239:0.009333:0.005850:0.013143:0.011738:0.013181:0.005850:0.013143:0.005850:0.017684:0.010314:0.011372:0.005850:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006388
tor preferred). :@0.524242:0.756049:0.659318:0.756049:0.659318:0.740293:0.524242:0.740293:0.006523:0.012604:0.005792:0.005330:0.013123:0.005702:0.012508:0.006042:0.012508:0.005792:0.005703:0.012508:0.013181:0.007100:0.005330:0.005330
The appropriate choice and sequenc-:@0.542426:0.772440:0.915149:0.772440:0.915149:0.756684:0.542426:0.756684:0.008197:0.011738:0.012508:0.009025:0.013143:0.013123:0.013123:0.005713:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.009025:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.009025:0.013143:0.011738:0.013181:0.009025:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.012450:0.006388
ing  of  treatments  lacks supporting  pro-:@0.524242:0.788831:0.915157:0.788831:0.915157:0.773075:0.524242:0.773075:0.003848:0.011738:0.012950:0.005330:0.006625:0.012604:0.006042:0.005330:0.006621:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007466:0.005330:0.006625:0.003848:0.013143:0.012450:0.009660:0.007466:0.011969:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.003848:0.011738:0.012950:0.005330:0.006616:0.013123:0.005715:0.012604:0.006388
spective data, and at present,  is largely :@0.524242:0.805222:0.920491:0.805222:0.920491:0.789466:0.524242:0.789466:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.009025:0.013181:0.013143:0.006523:0.013143:0.005330:0.009025:0.013143:0.011738:0.013181:0.009025:0.013143:0.006523:0.009025:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.005330:0.005330:0.003683:0.003848:0.007466:0.009025:0.003848:0.013143:0.005813:0.012950:0.012508:0.003848:0.010314:0.005330
empiric and based on tumour- and pa-:@0.524242:0.821613:0.915142:0.821613:0.915142:0.805857:0.524242:0.805857:0.012508:0.018049:0.013123:0.003848:0.005792:0.003848:0.012450:0.009333:0.013143:0.011738:0.013181:0.009333:0.013123:0.013143:0.007466:0.012508:0.013181:0.009333:0.012604:0.011738:0.009333:0.006523:0.011699:0.018049:0.012594:0.011699:0.005792:0.006388:0.009333:0.013143:0.011738:0.013181:0.009333:0.013123:0.013143:0.006388
tient-specific  factors.  Patients  should  be :@0.524242:0.838004:0.920485:0.838004:0.920485:0.822248:0.524242:0.822248:0.006523:0.003848:0.012508:0.011738:0.006523:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330:0.005548:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.005330:0.005540:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005553:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330:0.005550:0.013123:0.012508:0.005330
enrolled in  a  clinical trial wherever  pos-:@0.524242:0.854395:0.915163:0.854395:0.915163:0.838639:0.524242:0.838639:0.012508:0.011738:0.005707:0.012604:0.003848:0.003848:0.012508:0.013181:0.010160:0.003848:0.011738:0.005330:0.004820:0.013143:0.005330:0.004820:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.010160:0.006523:0.005792:0.003848:0.013143:0.003848:0.010160:0.015990:0.011738:0.012508:0.005711:0.012508:0.010660:0.012508:0.005792:0.005330:0.004814:0.013123:0.012604:0.007466:0.006388
sible.  Cytotoxic chemotherapy is  limited :@0.524242:0.870786:0.920460:0.870786:0.920460:0.855030:0.524242:0.855030:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.005330:0.005036:0.015644:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012440:0.010352:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013106:0.010314:0.010352:0.003848:0.007466:0.005330:0.005034:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330
to  patients who have progressed on  the :@0.524242:0.887177:0.920491:0.887177:0.920491:0.871421:0.524242:0.871421:0.006523:0.012604:0.005330:0.003031:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008370:0.015990:0.011738:0.012604:0.008370:0.011738:0.013143:0.010660:0.012508:0.008370:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.008370:0.012604:0.011738:0.005330:0.003031:0.006523:0.011738:0.012508:0.005330
above options, or where these treatment :@0.524242:0.903567:0.920489:0.903567:0.920489:0.887812:0.524242:0.887812:0.013143:0.013123:0.012604:0.010660:0.012508:0.006966:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006966:0.012604:0.005792:0.006966:0.015990:0.011738:0.012508:0.005709:0.012508:0.006966:0.006523:0.011738:0.012508:0.007466:0.012508:0.006966:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
options are not clinically appropriate, af-:@0.524242:0.919958:0.915161:0.919958:0.915161:0.904202:0.524242:0.904202:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.007582:0.013143:0.005713:0.012508:0.007582:0.011738:0.012604:0.006523:0.007568:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.007595:0.013143:0.013123:0.013123:0.005721:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330:0.007568:0.013143:0.006042:0.006388
fordable or available.:@0.524242:0.936349:0.726012:0.936349:0.726012:0.920593:0.524242:0.920593:0.006042:0.012604:0.005671:0.013181:0.013143:0.013123:0.003848:0.012508:0.005330:0.012604:0.005792:0.005330:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330